Navigation Links
Modifying an anti-cancer drug makes it more specific
Date:12/3/2007

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It can be used to treat these two distinct types of cancer because they are caused by related proteins tyrosine kinases. However, this lack of specificity for a single protein means that imatinib can also inhibit tyrosine kinases that mediate normal bodily functions and it has been reported that in some patients this causes a toxic effect on the heart. To address some of these problems, Ariel Fernndez and colleagues at Rice University, Houston, have engineered a modified form of imatinib (known as WBZ_4) that inhibited the tyrosine kinase behind GISTs (c-KIT) as effectively as imatinib did, and that neither inhibited the tyrosine kinase behind CML (BCR-Abl) nor had toxic effects on the heart when it was administered to mice. Importantly, WBZ_4 was as effective as imatinib at reducing tumor volume and weight in a mouse model of GISTs. As noted by George Demetri from the Dana-Farber Cancer Institute, Boston, in the accompanying commentary, this study gives hope that in the future it might be possible to construct ever-better agents that can be combined safely and effectively to manage, and eventually cure, many forms of human cancer.


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
2. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Web Portal Makes Organ Donation Easy
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Argonne researcher studies what makes quantum dots blink
8. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John ... Mr. Kelley, a recognized leader and mentor in the Denver area business ...
(Date:4/28/2016)... 2016 The report "Cryocooler Market ... Service (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, ... to 2022", published by MarketsandMarkets, the global market is ... at a CAGR of 7.29% between 2016 and 2022. ... 94 Figures spread through 159 Pages and in-depth TOC ...
(Date:4/28/2016)... New York, NY (PRWEB) , ... April 28, ... ... plan, QuickSTAT has made significant investments in recruiting top industry experts, and expanding ... IT Platform, which provides industry-leading tools for clients to manage their clinical trial ...
(Date:4/27/2016)... ... , ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” ... of Committee since 1987. Since then, he has served in a number of key ... for both the program and exposition committees. In his professional career, Dr. Gardner is ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):